Bioxytran, Inc. (BIXT)
USD 0.13
(-15.4%)
USD 0.13
(-15.4%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.89 Million USD | 1.57% |
| 2022 | 1.86 Million USD | -8.79% |
| 2021 | 2.04 Million USD | 30.51% |
| 2020 | 1.57 Million USD | 130.52% |
| 2019 | 681.35 Thousand USD | 256.79% |
| 2018 | 190.96 Thousand USD | 101.6% |
| 2017 | 94.72 Thousand USD | -4.23% |
| 2016 | 98.9 Thousand USD | -7.15% |
| 2015 | 106.51 Thousand USD | 2.59% |
| 2014 | 103.83 Thousand USD | 3.51% |
| 2013 | 100.31 Thousand USD | 240.3% |
| 2012 | 29.47 Thousand USD | 59.45% |
| 2011 | 18.48 Thousand USD | -58.34% |
| 2010 | 44.37 Thousand USD | -50.01% |
| 2009 | 88.76 Thousand USD | 2394.88% |
| 2008 | 3558.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 898.91 Thousand USD | 8.9% |
| 2024 Q2 | 825.45 Thousand USD | -14.25% |
| 2024 Q1 | 962.58 Thousand USD | -49.31% |
| 2023 Q3 | 1.84 Million USD | -5.63% |
| 2023 Q1 | 2.01 Million USD | 7.57% |
| 2023 FY | 1.89 Million USD | 1.57% |
| 2023 Q4 | 1.89 Million USD | 2.94% |
| 2023 Q2 | 1.95 Million USD | -2.8% |
| 2022 Q1 | 2.81 Million USD | 37.21% |
| 2022 Q2 | 3.09 Million USD | 9.97% |
| 2022 Q3 | 1.78 Million USD | -42.34% |
| 2022 Q4 | 1.86 Million USD | 4.84% |
| 2022 FY | 1.86 Million USD | -8.79% |
| 2021 Q3 | 1.84 Million USD | 10.39% |
| 2021 FY | 2.04 Million USD | 30.51% |
| 2021 Q4 | 2.04 Million USD | 10.91% |
| 2021 Q1 | 1.94 Million USD | 23.61% |
| 2021 Q2 | 1.67 Million USD | -13.77% |
| 2020 Q1 | 1.67 Million USD | 145.8% |
| 2020 Q3 | 1.61 Million USD | 0.73% |
| 2020 FY | 1.57 Million USD | 130.52% |
| 2020 Q4 | 1.57 Million USD | -2.58% |
| 2020 Q2 | 1.6 Million USD | -4.43% |
| 2019 Q1 | 623.76 Thousand USD | 226.63% |
| 2019 FY | 681.35 Thousand USD | 256.79% |
| 2019 Q2 | 587.93 Thousand USD | -5.74% |
| 2019 Q3 | 556.05 Thousand USD | -5.42% |
| 2019 Q4 | 681.35 Thousand USD | 22.53% |
| 2018 Q2 | 108.63 Thousand USD | 3.59% |
| 2018 Q3 | -2831.00 USD | -102.61% |
| 2018 Q1 | 104.86 Thousand USD | 10.7% |
| 2018 FY | 190.96 Thousand USD | 101.6% |
| 2018 Q4 | 190.96 Thousand USD | 6845.57% |
| 2017 Q2 | 110.34 Thousand USD | 3.18% |
| 2017 FY | 94.72 Thousand USD | -4.23% |
| 2017 Q3 | 86.55 Thousand USD | -21.56% |
| 2017 Q4 | 94.72 Thousand USD | 9.44% |
| 2017 Q1 | 106.95 Thousand USD | 8.13% |
| 2016 Q2 | 87.29 Thousand USD | -13.19% |
| 2016 FY | 98.9 Thousand USD | -7.15% |
| 2016 Q4 | 98.9 Thousand USD | 8.42% |
| 2016 Q3 | 91.22 Thousand USD | 4.51% |
| 2016 Q1 | 100.55 Thousand USD | -5.6% |
| 2015 Q4 | 106.51 Thousand USD | 14.1% |
| 2015 FY | 106.51 Thousand USD | 2.59% |
| 2015 Q1 | 107.27 Thousand USD | 3.31% |
| 2015 Q2 | 114.89 Thousand USD | 7.11% |
| 2015 Q3 | 93.35 Thousand USD | -18.75% |
| 2014 Q1 | 61.36 Thousand USD | -38.83% |
| 2014 FY | 103.83 Thousand USD | 3.51% |
| 2014 Q4 | 103.83 Thousand USD | 4.49% |
| 2014 Q3 | 99.37 Thousand USD | -7.84% |
| 2014 Q2 | 107.83 Thousand USD | 75.73% |
| 2013 Q4 | 100.31 Thousand USD | -5.53% |
| 2013 FY | 100.31 Thousand USD | 240.3% |
| 2013 Q1 | 22.3 Thousand USD | -24.34% |
| 2013 Q2 | 113.77 Thousand USD | 410.17% |
| 2013 Q3 | 106.18 Thousand USD | -6.68% |
| 2012 Q4 | 29.47 Thousand USD | -3.12% |
| 2012 FY | 29.47 Thousand USD | 59.45% |
| 2012 Q1 | 21.29 Thousand USD | 15.17% |
| 2012 Q2 | 29.86 Thousand USD | 40.25% |
| 2012 Q3 | 30.42 Thousand USD | 1.89% |
| 2011 Q2 | -155.02 Thousand USD | -448.39% |
| 2011 FY | 18.48 Thousand USD | -58.34% |
| 2011 Q3 | -12.97 Thousand USD | 91.63% |
| 2011 Q4 | 18.48 Thousand USD | 242.49% |
| 2011 Q1 | -28.26 Thousand USD | -163.7% |
| 2010 Q3 | 47.94 Thousand USD | -47.45% |
| 2010 Q2 | 91.22 Thousand USD | -0.49% |
| 2010 Q1 | 91.67 Thousand USD | 3.28% |
| 2010 FY | 44.37 Thousand USD | -50.01% |
| 2010 Q4 | 44.37 Thousand USD | -7.44% |
| 2009 FY | 88.76 Thousand USD | 2394.88% |
| 2009 Q2 | -32.87 Thousand USD | -334.99% |
| 2009 Q3 | 34.01 Thousand USD | 203.45% |
| 2009 Q1 | 13.99 Thousand USD | 0.0% |
| 2009 Q4 | 88.76 Thousand USD | 161.0% |
| 2008 FY | 3558.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 145055.267% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 66.381% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 95.563% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 860.722% |
| Rebus Holdings, Inc. | 305 Thousand USD | -522.595% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 130.12% |
| Qrons Inc. | 351.42 Thousand USD | -440.344% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -205.113% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 95.628% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 9404.753% |
| Skye Bioscience, Inc. | -5.72 Million USD | 133.19% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 87.953% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 53.888% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -372.544% |
| SQZ Biotechnologies Company | -36.23 Million USD | 105.24% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 15.311% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -104.804% |
| Mesoblast Limited | 55.85 Million USD | 96.6% |
| Marizyme, Inc. | 18.56 Million USD | 89.774% |
| Genus plc | 190.6 Million USD | 99.004% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 15.069% |
| Pharming Group N.V. | 109.8 Million USD | 98.271% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -120.742% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -56.432% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -179.252% |
| ContraFect Corporation | -6.02 Million USD | 131.512% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1310.374% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -64.347% |
| IMV Inc. | 7.67 Million USD | 75.244% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 65.486% |
| MultiCell Technologies, Inc. | 90.04 USD | -2108867.126% |
| ONE Bio Corp. | 9.04 Million USD | 78.994% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 358.715% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 85.332% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -38.812% |
| Q BioMed Inc. | 4.06 Million USD | 53.229% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 93.785% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -88.437% |
| Biomind Labs Inc. | 711.4 Thousand USD | -166.926% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.864% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 5.025% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 85.172% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -427.901% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1258.269% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -9458.132% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 13.763% |
| GB Sciences, Inc. | 1.74 Million USD | -8.676% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1133.209% |
| HST Global, Inc. | 96.79 Thousand USD | -1861.83% |
| CSL Limited | 10.52 Billion USD | 99.982% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -820.833% |
| Halberd Corporation | 144.72 Thousand USD | -1212.121% |
| Enzolytics Inc. | 981.65 Thousand USD | -93.44% |
| Agentix Corp. | 37.63 Thousand USD | -4946.143% |
| Resverlogix Corp. | 6.45 Million USD | 70.564% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 382.119% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.094% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 104.039% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 73.145% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 29.894% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 121.481% |
| AVAX Technologies, Inc. | -5.9 Million USD | 132.167% |
| Zenith Capital Corp. | 10.06 Thousand USD | -18768.382% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.179% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -847.411% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 20.415% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1054.292% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 10466.383% |
| Kadimastem Ltd | -253.1 Thousand USD | 850.256% |
| Helix BioMedix, Inc. | -2.57 Million USD | 173.887% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 90.635% |
| BioStem Technologies, Inc. | 4.47 Million USD | 57.538% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -843.541% |
| LadRx Corporation | -2.03 Million USD | 193.245% |
| Cell Source, Inc. | 9.23 Million USD | 79.431% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -198.963% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -198.963% |
| NovAccess Global Inc. | 2.17 Million USD | 12.832% |
| Affymax, Inc. | -5.59 Million USD | 133.927% |
| Itoco Inc. | 228.3 Thousand USD | -731.744% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1296.373% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 61.692% |
| Mobile Lads Corp. | 484.23 Thousand USD | -292.15% |
| CytoDyn Inc. | 20.26 Million USD | 90.628% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 293595.209% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 20588.178% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 75.358% |
| SYBLEU INC | 473.71 Thousand USD | -300.857% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 57.395% |
| International Stem Cell Corporation | 2.59 Million USD | 26.683% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2942.498% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 12.93% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 44.703% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 77.798% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -145.78% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 251.913% |
| Neutra Corp. | 52.18 Thousand USD | -3538.672% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 176.292% |
| PureTech Health plc | -167.19 Million USD | 101.136% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 875.358% |
| IXICO plc | -4.44 Million USD | 142.724% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 85.635% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 96.538% |
| CSL Limited | 10.52 Billion USD | 99.982% |
| Cellectis S.A. | -43.81 Million USD | 104.334% |